GC-Rise Pharmaceutical Closes US$15M Series B Financing Round

gc-rise-pharmaGC-Rise Pharmaceutical Co. Ltd, a Beijing, China-based pharmaceutical company focused on women and children’s healthcare, closed a US$15m Series B financing round.

The investment was led by OrbiMed, a healthcare and life sciences-focused investment firm. In conjunction with the financing, Dr. Jonathan Wang, Co-Founder and Senior Managing Director of OrbiMed Asia, joined GC-Rise’s Board of Directors.

The company intends to use the funds to strengthen commercialization capabilities, expand product portfolio and develop its online-to-offline (O2O) platform dedicated to women and children’s healthcare.

Founded in 2008, GC-Rise leverages its experience in clinical development, clinical trials and registration in China, and its commercial distribution, hospital sale and marketing force, to provide medical products for Chinese patients.
Led by Wren Zhang, Chief Executive Officer, and backed – beyond OrbiMed – by Inventages and Yifang Venture Capital, the company provides its international partners with service including policy interpretation, public affairs management, local registration, running of clinical trials, pricing, distribution to market promotion, brand-building and patient education.
It sales force has a network covering over 1,000 hospitals in China’s major cities and distributing products to 10,000 drug stores.

FinSMEs

02/09/2014

Join the discussion